Stay updated on PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.

Latest updates to the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.6.4 is now displayed, replacing v3.6.3. This indicates a new version of the page source rather than a change to study details or functionality.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3, reflecting a new version of the page.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.2, indicating a newer revision of the page.SummaryDifference0.0%

- Check53 days agoChange DetectedAdded new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment-status note ('No longer looking for participants'), improving visibility and user flow. The Intervention header was updated from 'Intervention / Treatment' to 'Intervention/Treatment' and the page revision tag updated to v3.6.0, while the old label was removed.SummaryDifference0.4%

- Check61 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing Revision: v3.5.4. This indicates an administrative update to the page's revision history.SummaryDifference0.0%

- Check82 days agoChange DetectedA new publication citation is added to the Publications section, reporting Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in PD-L1-unselected, metastatic NSCLC. The publication record is updated to Revision: v3.5.4, replacing the prior v3.5.3 entry.SummaryDifference0.1%

Stay in the know with updates to PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.